The information provided by in vitro tests is the basis for better decisions in health care.

With that concept in mind, Diasorin R&D efforts typically target innovative reagents allowing the development of informative assays addressing unresolved or partially resolved clinical needs. Following the technological transition from extractable reactants from natural sources to genetically engineered immunoreagents, process research over many years at Saluggia laboratories has optimised several expression systems with different characteristics (human transformed cells, E.coli, yeast, Baculovirus) making them easily available for the development of recombinant proteins with unique reactivities.

Such tools, combined with the opportunity given by the microparticle solid phase technology used in the LIAISON® product line, which allows controlled mixing of discrete reactivities, are used to develop assays able to maximize desired responses while minimizing unwanted interferences.

Partnership with medical research is vital to correctly identify diagnostic values for clinicians, especially in those cases, such as infectious serology, where reliability of diagnostic responses still may need sophisticated investigations including repeat testing using different assay technologies and iterative patterns involving specialized laboratories.

For this reason Diasorin has identified collaborations with leading international primary institutions in clinical research as a strategic step in its new product design concept.

This approach is presently driving new diagnostic concepts under development at Diasorin towards more accurate, automated assays in infectious serology (Borrelia burgdoferi and Treponema antibody testing), autoimmunity (ANA screen, ENA screen, anti ds DNA), bone & mineral metabolism, endocrinology and transplantation.